Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.



More Latest News

Electronic Prescribing Requirements
January 2, 2020

Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading


First Quarterly Performance Report Released for the 2019-2020 Fiscal Year
December 16, 2019

The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading